Home | Publications | Generic Drugs place holder
place holder place holder

Generic Drugs

Pipeline/Commercial Insight: Innovative Targeted Therapies

Smart Drugs' on Target for Increasing Growth

Publication Date   October 2005
Publisher   Datamonitor
Product Type   Report
Pages   348
ISBN Number   not applicable
Product Code   DAT392
Ask a question about this product?

Price £8,695.00

approximately: $15,353 | €11,025

Summary


The targeted therapies market is relatively new in comparison to the cytotoxic and anti-hormonal therapies markets, and will therefore continue to show double-figure growth across the seven major pharmaceutical markets to 2014. Despite products which have already established gold-standard status within specific tumor types, ample lucrative opportunities exist for pipeline candidates in the market.

Highlights

The market for existing targeted therapies was worth $5.1 billion in 2004, and is set to grow at a CAGR of 13.7% to reach $13.7 billion by 2014. This is due to the novelty of this market, allowing for further increasing sales of current marketed products, with no immediate threat from patent expiries and generic competition.This sustained growth will allow established products such as Genentech/Roche's Rituxan and Novartis' Glivec to maintain their blockbuster status, while allowing newer products such as Genentech/Roche's Herceptin, Avastin and Tarceva to break the $1 billion sales barrier within the forecast period.The introduction of high-potential pipeline products will increase the total market value of targeted therapies to $19.2 billion by 2014. Those products developed to inhibit multiple pathways show the most promise, particularly Onyx Pharmaceuticals/Bayer's sorafenib and Bristol-Myers Squibb's dasatinib, with forecast sales of over $800m by 2014.

Scope

  • Overview of the current targeted therapies market, including profiles of key products and events impacting each during 200414
  • Examination of the targeted therapies pipeline with in-depth clinical and commercial profiles of Phase III candidates, plus expert opinion
  • Seven-market sales forecasts from 2004 to 2014 for branded targeted therapies and key pipeline candidates
  • Detailed discussion of key strategic issues in the targeted therapies market, plus three commercial impact and lifecycle management case studies

Reasons to Purchase

  • Understand market specific drivers and predict the future potential of key marketed and pipeline targeted therapies
  • Assess the impact of product launches and identify the opportunities and risks for key products within the targeted therapies market
  • Adopt knowledge to drive strategic planning for marketed products and optimize the market penetration of new entrants

Content


  • Chapter 1 Executive Summary
    • Scope of analysis
    • Datamonitor insight into the targeted therapies market
  • Chapter 2 Pipeline Overview
    • Pipeline overview
    • Pipeline by developmental phase & class of drug
    • Signal transduction inhibitors and angiogenesis inhibitors constitute over half the current targeted therapies pipeline
    • The current late-phase pipeline is relatively sparse due to the novelty of this market
    • Pipeline by molecular target
    • Signal transduction inhibitors
    • Angiogenesis inhibitors
    • Apoptosis stimulators
    • HDAC inhibitors
    • Cell cycle regulators
    • Other monoclonal antibodies
    • Pipeline by indication
    • The 'big four' tumor types, plus melanoma and RCC are the most popular indications for development
    • Non-Hodgkin's lymphoma dominates the pipeline within the hematological malignancies
    • Pipeline by company
    • At least 138 companies are involved in the current targeted therapies pipeline
    • Top three companies in terms of marketed and pipeline products are Genentech, AstraZeneca and Pfizer
    • Key metrics
    • Datamonitor pipeline assessment summary
  • Chapter 3 Pipeline Dynamics
    • A diverse range of disease subtypes
    • Genetic basis of cancer evolution
    • Tumorigenesis is the result of cooperative accumulated mutations
    • Existing pharmacotherapy approaches provide limited treatment benefit
    • Cytotoxic drugs lack specificity
    • Hormonal or endocrine therapy provides incremental benefit in selected tumors
    • Optimizing current treatment strategies is paramount
    • The emergence of targeted treatment heralds a revolution in cancer pharmacotherapy
    • Dynamic cancer market offers significant commercial opportunity
    • Ongoing sales growth drives the market
    • Intensive R&D produces a rich developmental pipeline
    • Growing patient population and significant unmet needs propel innovation in the cancer market
    • Clinical and strategic threats to the commercialization of cancer drugs
    • Progressively rising R&D costs threaten industry productivity
    • Pharmacoeconomic pressures drive payers to implement restrictive pricing and reimbursement policies
    • Increased therapeutic and generic competition results in reduced periods of market exclusivity
    • Segmentation of market will require changes in clinical trial methodology
  • Chapter 4 Market Definition & Pipeline Classification
    • Targeted therapies overview
    • The development of innovative targeted therapies
    • Market definition
    • L1X3 - Antineoplastic monoclonal antibodies
    • L1X9 - All other antineoplastics
    • Classification of pipeline products
    • Signal transduction inhibitors
    • Angiogenesis inhibitors
    • Apoptosis stimulators
    • Histone deacetylase inhibitors
    • Cell cycle inhibitors
    • Pipeline comparator
    • Current market situation
  • Chapter 5 Marketed Products Forecast Analysis
    • Country-specific assumptions and effects
    • Effect of Medicare Modernization Act in the US
    • Biennial price cuts in Japan
    • National Institute of Clinical Excellence in the UK
    • Product assumptions and effects
    • Signal transduction inhibitors
    • Angiogenesis inhibitors
    • Apoptosis stimulators
    • Other monoclonal antibodies
    • Others
    • Forecasts
  • Chapter 6 Pipeline Signal Transduction Inhibitors Analysis & Forecasts
    • Pipeline overview
    • Onyx Pharmaceuticals/Bayer's sorafenib (BAY 43-9006)
    • Drug profile
    • Clinical trial data
    • Datamonitor comments
    • Pfizer's Sutent (sunitinib malate)
    • Drug profile
    • Clinical trial data
    • Datamonitor comments
    • Abbott Laboratories' Xinlay (atrasentan)
    • Drug profile
    • Clinical trial data
    • Datamonitor comments
    • Abgenix/Amgen's ABX-EGF (panitumumab)
    • Drug profile
    • Clinical trial data
    • Datamonitor comments
    • GlaxoSmithKline's lapatinib (GW-572016)
    • Drug profile
    • Clinical trial data
    • Datamonitor comments
    • Schering-Plough's Sarasar (lonafarnib)
    • Drug profile
    • Clinical trial data
    • Datamonitor comments
    • Wyeth's temsirolimus (CCI-779)
    • Drug profile
    • Clinical trial data
    • Datamonitor comments
    • AstraZeneca's Zactima (ZD-6474)
    • Drug profile
    • Clinical trial data
    • Datamonitor comments
    • Janssen/Johnson & Johnson's Zarnestra (tipifarnib)
    • Drug profile
    • Clinical trial data
    • Datamonitor comments
    • Bristol-Myers Squibb's dasatinib (BMS-354825)
    • Drug profile
    • Clinical trial data
    • Datamonitor comments
    • Novartis's AMN-107
    • Drug profile
    • Clinical trial data
    • Datamonitor comments
    • Kosan Biosciences' 17-AAG
    • Drug profile
    • Clinical trial data
    • Datamonitor comments
    • Forecasts
    • Datamonitor drug assessment summary
  • Chapter 7 Pipeline Angiogenesis Inhibitors Analysis & Forecasts
    • Pipeline overview
    • National Cancer Institute's CAI (L-651582, carboxyamidotriazole)
    • Drug profile
    • Clinical trial data
    • Datamonitor comments
    • terna Zentaris's Neovastat (AE-941)
    • Drug profile
    • Clinical trial data
    • Datamonitor comments
    • Novartis/Schering AG's PTK-787 (vatalinib)
    • Drug profile
    • Clinical trial data
    • Datamonitor comments
    • Pfizer's AG-13736
    • Drug profile
    • Clinical trial data
    • Datamonitor comments
    • Forecasts
    • Datamonitor drug assessment summary
  • Chapter 8 Pipeline Apoptosis Stimulators Analysis & Forecasts
    • Pipeline overview
    • Genta's Genasense (oblimersen)
    • Drug profile
    • Clinical trial data
    • Datamonitor comments
    • Telik's Telcyta (TLK286)
    • Drug profile
    • Clinical trial data
    • Datamonitor comments
    • Xenova's TransMID (XR-311)
    • Drug profile
    • Clinical trial data
    • Datamonitor comments
    • Forecasts
    • Datamonitor drug assessment summary
  • Chapter 9 Pipeline Histone Deacetylase Inhibitors Analysis & Forecasts
    • Pipeline overview
    • Gloucester Pharmaceuticals' FK-228 (depsipeptide)
    • Drug profile
    • Clinical trial data
    • Datamonitor comments
    • Forecasts
    • Datamonitor drug assessment summary
  • Chapter 10 Other Pipeline Monoclonal Antibodies Analysis & Forecasts
    • Pipeline overview
    • Millennium Pharmaceuticals/BZL Biologics's MLN-2704
    • Drug profile
    • Clinical trial data
    • Datamonitor comments
    • Forecasts
    • Datamonitor drug assessment summary
  • Chapter 11 Commercial Impact & Lifecycle Management: Case Studies
    • Introduction
    • Case study
    • Iressa and Tarceva: why the difference?
    • Case study
    • Strategies for success: Genentech
    • Strategies for success: Novartis
    • Case study
    • The pharmacoeconomic challenges associated with targeted therapies
  • Appendix A - Market Data & Major Brand Key Facts
    • L1X3 (antineoplastic monoclonal antibodies) class market data
    • L1X9 (all other neoplastics) class market data
    • Sales data and forecasts
    • PowerPoint Executive Presentation
  • Appendix B - Sales Forecasts
    • US forecasts
    • Japan forecasts
    • France forecasts
    • Germany forecasts
    • Italy forecasts
    • Spain forecasts
    • UK forecasts
    • EU5 forecasts
    • Global forecasts
  • Appendix C
  • List of tables
  • List of figures
    • Methodology
    • Datamonitor forecast methodology
    • Datamonitor drug assessment methodology
  • List of abbreviations
    • Contributing experts
    • US opinion leader
    • US opinion leader
    • Bibliography
    • About Datamonitor
    • About Datamonitor Healthcare
    • About the Oncology analysis team
    • Disclaimer